Corridome

ImmunoGen, Inc

Sale Life Sciences & Pharma November 30, 2023

From an SEC filing dated Nov 30, 2023

  1. ImmunoGen, Inc agreed to be sold to AbbVie, announced on Nov 30, 2023.

    8-K

  2. Goldman Sachs & Co.firm and Lazard Freres & Co.firm advised the seller.

    8-K

  3. J.P. Morgan Securitiesfirm and Morgan Stanley & Co.firm advised the buyer.

    8-K

  4. The filing puts the value at $10.1B.

    8-K

  5. Goldman Sachs & Co.firm also worked on Prudential of Brazil and Prudential of Mexicodeal, on Oct 20, 2026.

    8-K

Parties

first 2 of 5

PartyRoleSource
AbbVieBuyer8-K
Goldman Sachs & Co.Seller's adviser8-K

3 more parties

Sign up free to see all 5.

Sign up free

Value

KindAmountBasisSource
Disclosed$10.1Bequity value8-K

More deals

first 2 of 13

DateDealFirmsSource
Oct 26, 2026Surgery Partners, Inc · SaleBain Capital Private Equity, Centerview Partners8-K
Oct 21, 2026American Oncology Network, Inc · SaleMoelis & Company, Citigroup Global Markets8-K

11 more deals

Deals with Goldman Sachs & Co., Lazard Freres & Co. and 2 more firms.

Sign up free to see the first 5, or become a member to see all 13.

Sign up freeBecome a member

On file

Date as stated
November 30, 20238-K
Filed by
AbbVie Inc. (ABBV)8-K
Status
Announced8-K

Browse the register